NCT06756217
68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC
Recruiting · Not specified · Ruijin Hospital · registry updated 2025-01-01
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The purpose of this study is to explore the effectiveness of 68Ga-grazytracer PET/CT in early evaluation of neoadjuvant immunotherapy response in resectable NSCLC.
Inclusion
- Pre-treatment stage as clinical IB-IIIA (AJCC/UICC 8th Edition);
- Curative resectability has to be explicitly verified by the experienced surgical investigator;
- Histologically confirmed diagnosis of primary non-small lung cancer.
- Men and women aged 18 Years to 75 Years;
- Eastern Cooperative Oncology Group (ECOG) performance status: 0-1;
- expected survival ≥ 6 months;
Exclusion
- Histologically confirmed were NOT NSCLC;
- Lung cancer that can not be resected or has distant metastasis, or for other reasons can not tolerate surgery;
- Patients with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colorectal, endometrial, cervical, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period;
- Any active or history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications. The subjects were innate or acquired immunodeficiency (such as HIV), or active hepatitis (hepatitis B reference: HBsAg) positive; Hepatitis C reference: HCV antibody positive;
- Uncontrolled diabetes or fasting blood glucose ≥11.0 mmol/L on the day of the test;
- Women who are or may become pregnant, and lactating women are excluded;